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Abstract: Synthesis of platinum(II) conjugate with acetylated betulinic acid tris(hydroxymethyl)
aminomethane ester (BATRIS) is presented (BATRISPt). HR-ESI-MS and multinuclear NMR
spectroscopy, as well as elemental analysis were used for characterization of BATRISPt. Cytotoxicity
(3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), crystal violet (CV), and
sulforhodamine B (SRB) assays) of BA, BATRIS, BATRISPt, and cisplatin were assessed on seven
different tumor cell lines: melanoma B16, colon HCT116 and DLD-1, adenocarcinoma HeLa, breast
MCF-7, and anaplastic thyroid tumor 8505C and SW1736; as well as normal MRC-5 fibroblasts.
Furthermore, the effect of the mentioned compounds on the apoptosis (Annexin V/PI assay) and
autophagy induction (acridine orange (AO) assay) as well as caspase 3, 8, and 9 activation were
investigated on the selected B16 melanoma cell line. BATRISPt showed lower activity than BA,
BATRIS, or cisplatin. All tested compounds triggered apoptosis in B16 cells. Induction of autophagy
was observed in B16 cells exposed only to BATRIS. On the other hand, new conjugate activates
caspases 8 and 9 in B16 cells with higher impact than BATRIS or cisplatin alone.
Keywords: betulinic acid; cisplatin; drug conjugate; apoptosis; autophagy
1. Introduction
Metal-based drugs (e.g., cisplatin, oxaliplatin), natural products and their derivatives (e.g.,
paclitaxel, doxorubicin), or even their combination (e.g., 5-fluorouracil, oxaliplatin, irinotecan) are
frequently used as chemotherapeutic drugs for cancer treatment [1–4]. However, along with killing
the cancer cells, such drugs cause severe side effects [5]. While the combined application of few drugs
is a common approach in the treatment of cancer, and numerous experimental data both in vitro and
in vivo have confirmed the efficacy of such treatment [6–8], the conjugation of platinum(II) complexes
to biologically (antitumor) active agents is not as profoundly investigated [9–12]. The first approach,
combinational chemotherapy, depends on the biological properties of the single components. For
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instance, how such compounds can be delivered, metabolized, and how and to which magnitude they
may enter the tumor cells. On the other side, two components covalently linked to each other—double
drug [13], presumably—may possess different behavior than single components alone.
Even lower in activity than paclitaxel or doxorubicin [14,15], a cell-type-specific antitumor active
compound betulinic acid (BA) has drawn more attention in the last few years and is still explored
by many groups [16–24]. BA is a naturally occurring pentacyclic triterpenoid which is isolated from
the bark of several species of plants (e.g., white birch). Betulinic acid and its derivatives present
compounds with numerous biological activities—for instance, antioxidant, antiviral, antimicrobial,
anti-inflammatory, antidiabetic, immunomodulatory, etc. [25,26]. However, investigations on betulinic
acid in the last few years have been pointed toward the field of antitumor properties [27–31].
We recently reported the synthesis and characterization of the new series of betulinic
acid–cisplatin conjugates, which are both apoptosis inducing agents [32]. However, their cytotoxicity
was found to be lower than parental drugs cisplatin and betulinic acid. Herein we report
on the synthesis, characterization, and in vitro activity of acetylated betulinic acid derivative
tris(hydroxymethyl)aminomethane (TRIS) ester conjugated with PtCl3-fragment.
2. Results and Discussion
2.1. Synthesis and Characterization
The reaction of dichloromethane solution of acetylated betulinic acid tris(hydroxymethyl)
aminomethane ester (BATRIS) and [K(18-cr-6)]2[Pt2Cl6] afforded BATRISPt complex (Scheme 1) in
almost quantitative yield. This complex was isolated as a yellow solid.
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electrospray ionisation mass spectrometry), as well as multinuclear NMR spectroscopy. The 
stoichiometric formula of BATRISPt is in agreement with elemental analysis. HR-ESI-MS recorded in 
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Scheme 1. Synthesis of BATRISPt complex and numeration of H and C atoms.
Th isolated compound w s characterized with ementa a alysis, HR-ESI-MS (High-resolution
electrospray ionisation mass spectrometry), as well as multinuclear NMR spectroscopy. The
stoichiometric formula of BATRISPt is in agreement with elemental analysis. HR-ESI-MS recorded in
negative ion mode gave evidence for the molecular composition of the platinum(II) anionic complex.
Namely, the {BATRISPt–[K(18-cr-6)]}− ion (m/z = 902.30213) with the characteristic expected isotope
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pattern was detected (Figure A1 in Appendix A). In positive ion mode, [K(18-cr-6)]+ ion was detected
at m/z = 303.12055.
In the 1H and 13C NMR spectra of BASTRISPt, chemical shifts arising from lupane moiety were
found at expected values [24]. Hydrogen atoms from the TRIS moiety in the 1H NMR spectrum showed
coordination-induced shifts up to 0.5 ppm (C3’H and C4’H). Similar behavior upon coordination was
observed for TRIS moiety in 13C NMR spectrum; for example, C2’ atom is deshielded for ca. 14 ppm in
comparison to the same carbon atom in BATRIS [30]. Chemical shift at 70.7 ppm corresponds to the
carbon atoms from 18-cr-6, while appropriate hydrogen atoms at 3.61 ppm in the 1H-NMR spectrum
were observed [33]. The 195Pt NMR spectrum showed exclusively the presence of one complex with
the resonance at −1921 ppm. The chemical shift is in good agreement with those observed for [Cl3,N]
donor set; e.g., K[PtCl3(NH3)] complex δ is −1884 ppm [34].
The stability of the BASTRISPt complex was evaluated using 1H-NMR spectroscopy. The complex
was dissolved in DMSO-d6 and recorded over time. Additionally, the same experimental settings
were used for BATRISPt dissolved in CDCl3. As expected, it could be proven that BATRISPt did not
decompose in CDCl3 over the investigated period of time (0, 4, and 24 h). The 1H NMR spectrum
of BATRISPt in DMSO-d6—recorded immediately after dissolution—gave a comparable chemical
shifts pattern to one obtained in CDCl3. Direct comparison of the resonances of the hydrogen atoms
belonging to TRIS moiety from BATRIS (in DMSO-d6) or BATRISPt (0, 4 and 24 h) clearly pointed
out that proton resonances from the free ligand in BATRISPt were not observed. Thus, it could be
clearly demonstrated that ligand remained coordinated to platinum center. Moreover, there was no
precipitate during the investigated reaction time. 1H NMR spectrum in DMSO-d6 after 4 h showed
decrease (ca. 25%) in intensities of the proton resonances near platinum(II) coordination sphere (C3’H2
and C4’H2), indicating possible coordination of solvent molecules. After 24 h, the substitution of Cl−
ligands with DMSO-d6 in BATRISPt took place to a greater extent (ca. 45%). Furthermore, this confirms
that in the coordination sphere of platinum(II), only substitution of Cl− ligand(s) occurs. Nevertheless,
for in vitro studies, stock solutions of DMSO were prepared freshly and diluted immediately with
nutrition medium to various working concentrations in order to hinder solvolysis.
2.2. Cytotoxicity of BATRISPt
Initially it was reported that betulinic acid is selectively cytotoxic for the melanoma cell lines,
with IC50 values ranging from 2.4 to 10.3 µM (1.1–4.8 µg/mL) [35]. Since then, a growing number of
tumor cells derived from colon, prostate, breast, lung, squamous, and glioma were tested, while the
corresponding IC50 values for different cancer cells were around 43 µM (20 µg/mL), whereas normal
cells were unaffected by BA treatment [36]. However, limited solubility and sometimes modest activity
represent a challenge for different modification of this compound. The idea reported herein concerns a
hybrid molecule comprised of two well-known apoptosis-inducing entities.
Seven different tumor cell lines (melanoma B16, colon HCT116 and DLD-1, adenocarcinoma
HeLa, breast MCF-7, and anaplastic thyroid tumor 8505C and SW1736) were used for the assessment
of viability upon exposure to BA, BATRIS, BATRISPt, and cisplatin. For determination of the viability,
three different tests were applied. The MTT (3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium
bromide) test is based on the measurement of mitochondrial respiration, crystal violet (CV) on the
quantity of nucleic acids while sulforhodamine B (SRB) on the protein content. Therefore, by comparing
the data obtained by those assays, initial information about the mechanism of drug action can be
obtained. Cells were exposed to drugs for 96 h, and subsequently IC50 values were assessed (Figure 1).
As presented in Figure 1, it is obvious that all tested cell lines were sensitive to the treatment with
BA. IC50 values obtained by MTT and SRB are in concordance and mostly significantly lower than
those obtained by CV assay. The discrepancy in IC50 values obtained by these tests indicated that
these agents probably blocked cell cycle division in G2M or S phase of the cell cycle. Therefore, the
quantity of stained DNA in cell cultures is not a reflection of the number of viable cells. Detected IC50
values are in the range of that previously reported in the literature [27–31]. As already shown in the
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literature [30], modification of BA with TRIS (→ BATRIS) strongly amplified the efficacy of BA in all
tested cells, and IC50 values obtained by applied methods were well synchronized, suggesting that
this chemical intervention changed the mode of drug action.
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Figure 1. IC50 values (µM) (SD < 10%) of the various tumor cells and normal fibroblasts MRC-5
treated with investigated compounds determined with MTT (), CV () and SRB () assays (96 h).
IC50 > 50 µM. BA: betulinic acid; BATRIS: acetylated betulinic acid tris(hydroxymethyl) aminomethane
ester; BATRISPt: platinum(II) conjugate with BATRIS; CV: crystal violet; MTT: 3-(4,5-dimethythiazol-
2-yl)-2,5-diphenyltetrazolium bromide.
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In order to intensify the cytotoxicity of BATRIS, PtCl3-moiety was conjugated with the BATRIS
(→ BATRISPt). However, unexpectedly, BATRISPt was less potent than BATRIS and BA, as well
as cisplatin. The obtained data showed that decreased efficacy of conjugate compound BATRISPt
might be caused by the activation of some cytoprotective mechanism inside of the cell, which in
final point neutralizes the toxicity of the treatment. Data presented herein are in concordance with
recently reported results, where different betulinic acid derivatives conjugated with PtCl2-fragment
were tested [32]. However, strong selectivity of some of these synthetic compounds apart from lower
cytotoxicity indicated that they might have potential as anticancer agents.
On the other hand, treatment of human immortalized fibroblasts MRC-5 with cisplatin alone
resulted in completely abolished viability showing even worse effect in comparison to tumor cells.
Similarly, viability of normal fibroblast was even more affected by BA and BATRIS in comparison to
cancer cells. This data opposed to previously observed high selectivity of BA for cancer cells [32] and
definitely require further confirmation in diverse types of normal cells. Conjugate BATRISPt was found
to be less toxic to primary cells in comparison to maternal drugs. Even though the IC50 values are in
line or even higher with one observed for few cell lines, selectivity was proven for B16 and HCT116
cell lines, indicating that in spite of lower cytotoxicity, conjugated drug deserves further evaluation.
2.3. Mechanism of Action
To evaluate the reason for neutralization of BATRIS toxicity in BATRISPt, B16 cells were treated
with compounds for 48 h and further stained by acridine orange/ethidium bromide (AO/EtBr)
(Figure 2). Analysis of morphological changes induced by the treatments showed that BATRIS as well
as cisplatin dramatically decreased the number of viable cells. Numerous rounded cells and cells
with picknotic nuclei and condensed chromatin were visible, indicating that both compounds induced
apoptotic cell death [37].
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The fact that BA induced apoptosis in several different cancer cell lines through multiple pathways
is well described. BA treatment caused distinct morphological changes like cell shrinkage, DNA
fragmentation, nuclear condensation, and membrane blebbing in sensitive cells [38]. Several studies
revealed that BA directly targeted mitochondria, resulting in decreased mitochondrial membrane
potential, up-regulation of death receptors, and interactions with other agents. Accumulated
experimental evidence showed that the activation of caspases, MAP kinase cascade, the modulation of
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NF-κB signaling, intensified production of reactive oxygen species, and the inhibition of topoisomerase
I are behind the tumoricidal action of BA. In concordance, by data of viability tests, conjugate BATRISPt
was remarkably less potent since a significantly higher number of cells was present in culture exposed
to this compound. Volume and size of the cells were enhanced in comparison to control. Their
morphology, described as flat with dendritic-like processes, could be the sign of more differentiated
phenotype or senescence state [39].
Furthermore, annexin V (Ann)/propidium iodide (PI) staining was performed. As seen in
Figure 3a, B16 cells exposed to all treatments were conducted to apoptosis. In concordance with
cell viability decrease, the percentage of early apoptotic cells was the highest in the presence of
BATRIS and cisplatin in cell culture. However, treatment with BATRISPt resulted in a lower amount
of early apoptotic cells (Ann+PI−), confirming once more that the combination of two cytotoxic
molecules, instead of amplification, minor inhibition of the activity occurs. Knowing that autophagy
can confront the apoptosis and is often responsible for decreased efficacy of the apoptosis-inducing
agents, B16 treated cells were stained by AO. Crosstalk between apoptosis and autophagy may be
crucial for the balance between cell survival and death. Triggering of autophagy by tumor cells as a
cytoprotective mechanism able to suppress apoptosis induced by chemotherapy seems to be a general
phenomenon and one of the major problems in cancer therapy efficacy. Cytoprotective effects due
to intensified autophagy were reported in different tumor types exposed to gefitinib, erlotinib, and
celecoxib, suggesting that the concomitant use of autophagy inhibitors with chemotherapy might
be beneficial [40]. On the other hand, while increasing evidence showed that autophagy may be
responsible for cell death in certain settings, it is clear that this process and its interplay with apoptosis
determines the fate of cells upon therapy [41].
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The intensity of the red fluorescence correlates with the presence of acidic vesicles recognized as
autophagosomes [42]. Surprisingly, autophagy was the most intensive in cultures exposed to BATRIS,
since the addition of the PtCl3-moiety abrogated this process, bringing it to the level of cisplatin alone
(Figure 3b). It is indicative that in this experimental setting the process of autophagy serves as a dying
process rather than a cytoprotective one in BATRIS-exposed cells. In addition, the decreased amount
of autophagy resulted in diminished toxicity in BATRISPt-treated cultures. To explore a possible
connection between caspase activation and observed effect, the activity of caspase 3, 8, 9 were analyzed
(Figure 3c).
Paradoxically, BATRISPt, even with the worst anticancer potential in this study, activated caspases
8 and 9 more powerfully than other compounds. Recently, it has been described that caspases are
important mediators in crosstalk between autophagy and apoptosis [43]. Activated caspases are
able to cleave some autophagic proteins like Beclin-1, p62, Atg3, Atg4D, Atg5, Atg7, and AMBRA1,
leading to the inactivation of autophagy. Caspase 8 cleaves Atg3, targeting the conserved LETD
sequence (Atg3 amino acids 166–169), shutting down autophagic activity. On the other hand, caspases
are able to cleave some pro-autophagic proteins, transforming them into pro-apoptotic proteins.
In addition, autophagy can modulate the activity of caspases. Caspase 8 is known as an essential
trigger involved in death receptor-induced apoptosis, but nowadays the increasing evidence indicates
that caspase 8 also participates in regulating autophagy [43]. Since it has been described that caspases
are also involved in autophagy inhibition and that we hypothesized that autophagy contributes to
the dying process in BATRIS-treated cells, it could be possible that the activated caspases by the
BATRISPt down-regulated autophagy and subsequently protected cells against autophagy-mediated
destruction [43–45]. According to this, diminished toxicity is probably the result of confrontation
between programmed cell death apoptosis and autophagic cell death.
3. Materials and Methods
3.1. General Remarks
Commercially-pure chemicals were used as received from distributor. [K(18-cr-6)]2[Pt2Cl6] was
synthesized according to the reported procedure [33]. The elemental analysis (C, H, N) was carried
out on a CHNS-93 (LECO) elemental analyzer. High-resolution ESI mass spectra were obtained from
a Bruker Apex III Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer (Bruker
Daltonics, Bremen, Germany) equipped with an Infinity cell, a 7.0 T superconducting magnet (Bruker),
an rf-only hexapole ion guide, and an external APOLLO electrospray ion source (Agilent, off-axis
spray). The sample solutions were introduced continuously via a syringe pump with a flow rate of
120 µL·h−1. The data were evaluated using Bruker Compass DataAnalysis 4.0 (Bremen, Germany).
The 1H, 13C, and 195Pt NMR spectra were recorded on a VXR 400 NMR spectrometer in CDCl3 at
27 ◦C. Chemical shifts in the 1H and 13C NMR spectra are relative to CHCl3 (δ = 7.24 ppm) and CDCl3
(δ = 77.0 ppm) as internal references. The 195Pt NMR chemical shift was determined using H2[PtCl6]
as external standard (δ = 0 ppm). For stability studies, BATRISPt was dissolved in CDCl3 or DMSO-d6,
and 1H NMR spectra were recorded over 0 h, 4 h, and 24 h on a Bruker Avance III 500 (Bremen,
Germany); chemical shifts were referenced to internal standard TMS (tetramethylsilane).
3.2. Synthesis of the Platinum(II) Complex, BATRISPt
[K(18-cr-6)]2[Pt2Cl6] (50 mg, 0.04 mmol) and BATRIS (50 mg, 0.08 mmol) were stirred in CH2Cl2
(10 mL) for 3 h. The color of the reaction mixture changed from pink to yellow. Afterwards, solvent was
evaporated and product was dried in vacuum. Yield: 49 mg (98%). Anal. Calc. for C48H83Cl3KNO12Pt
(1206.72): C, 47.78; H, 6.93; N, 1.16. Found: C, 47.14; H, 6.63; N, 1.11. HR-ESI-MS m/z: 902.30213
{BATRISPt–[K(18-cr-6)]}−, calcd. for [C36H5935Cl3NO6195Pt]− 900.30611; 303.12055 [K(18-cr-6)]+, calcd.
for [C12H24O6K]+ 303.12045. Numeration of H and C atoms is shown in Scheme 1. 1H NMR (400 MHz,
CDCl3): δ 0.76 (m, 1H, C5H), 0.77 (s,3H, C24H3), 0.84 (s, 3H, C23H3), 0.88 (s, 3H, C25H3), 0.93 and 1.81
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(m, 2H, C1H2), 0.96 (s, 3H, C26H3), 1.03 and 1.84 (m, 2H, C15H2), 1.19 and 1.87 (m, 2H, C12H2), 1.30
and 1.61 (m, 2H, C11H2), 1.35 and 1.52 (m, 2H, C7H2), 1.38 and 1.56 (m, 2H, C6H2), 1.41 (m, 1H, C9H),
1.42 and 2.17 (m, 2H, C16H2), 1.54 and 2.22 (m, 2H, C21H2), 1.62 and 2.24 (m, 2H, C22H2), 1.76 (s, 3H,
C30H3), 1.78 (m, 2H, C2H2), 1.81 (m, 1H, C18H), 2.08 (s, 3H, C2′ ′H3), 2.09 (m, 1H, C13H), 2.89 (m, 1H,
C19H), 3.61 (s, 24H, C18-cr-6H), 4.08 (m, 2H, C3′H2 and m, 2H, C4′H2), 4.24 (dd, 2H, C1′H2), 4.37 (m,
1H, C3H), 4.53 (s, H, C29H), 4.65 (s, H, C29H). 13C NMR (100 MHz, CDCl3): δ 15.0 (C27), 15.2 (C24),
15.5 (C25), 17.2 (C26), 18.3 (C6), 19.0 (C29), 20.3 (C11), 22.7 (C2′ ′), 24.5 (C2), 26.9 (C12), 28.7 (C23), 29.5
(C21), 31.1 (C15), 33.2 (C16), 35.9 (C7), 36.0 (C22), 36.1 (C4), 36.8 (C10), 37.2 (C13), 37.4 (C1), 39.7 (C8),
41.4 (C14), 45.9 (C18), 48.4 (C19), 49.5 (C9), 55.7 (C5), 62.0 (C17), 54.4 (C1′), 61.5 and 61.6 (C3′ and C4′),
70.7 (C18-cr-6), 79.9 (C2′), 108.8 (C30), 149.3 (C20), 170.0 (C1′ ′), 174.5 (C28). 195Pt NMR (86 MHz, CDCl3):
δ −1921 ppm.
3.3. Preparation of Drug Solution
Compound BA, BATRIS, and BATRISPt (all at concentration 20 mM) were dissolved in
DMSO. Before the treatment, working solutions were made in culture medium. Cisplatin stock
solution was prepared immediately before treatment in DMF (20 mM). The working solutions
were obtained from diluting appropriate stock solutions in nutrition medium (HEPES-buffered
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) RPMI-1640 medium supplemented with 10%
heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 0.01% sodium pyruvate, penicillin
(100 U/mL) and streptomycin (100 µg/mL)). The final concentrations of DMSO and DMF did not
exceed 0.5% (the concentration non-toxic to the cells).
3.4. Cell Culture and Conditions
Culture medium RPMI-1640 was obtained from Biowest (Superlab, Belgrade, Serbia). Fetal calf
serum (FCS), phosphate-buffered saline (PBS), dimethyl sulfoxide (DMSO), crystal violet (CV) and
propidium iodide (PI) were obtained from Sigma (St. Louis, MO, USA). 3-(4,5-dimethythiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) was obtained from AppliChem (Promedia doo, Kikinda,
Serbia). Annexin V-FITC (AnnV) was from BD (Pharmingen, San Diego, CA, USA) and specific
substrate of caspases 3 (Ac-DEVD-pNA), 8 (Ac-IETD-pNA), and 9 (Ac-LEHD-pNA) were from Axxora
(Loerrach, Germany). Pen-Strep solution was from Biological Industries (Cromwell, CT, USA). The
cell lines 8505C, A253, A549, A2780, and DLD-1 were included in this study. Cell lines HCT116,
DLD-1, HeLa, MCF-7, 8505C, and SW1736 were kindly provided by Dr. Thomas Müller (Department
of Hematology/Oncology, Martin Luther University of Halle-Wittenberg, Germany), while B16 and
MRC-5 as kind gift from Prof. Siniša Radulovic´ (Institute for Oncology and Radiology of Serbia). Cells
were grown in nutrition medium at 37 ◦C in a humidified atmosphere with 5% CO2. Density of cells at
seeding time in 6- and 96-well plates was as previously described [46].
3.5. MTT and CV Assays for Cellular Viability
Cells were incubated in the presence of experimental compounds during 96 h with subsequent
estimation of cellular viability. For MTT test, cells were incubated with MTT solution (0.5 mg/mL) at
37 ◦C for around 1 h till formazan crystals were made. Dye was discarded, and produced formazan
was dissolved in DMSO. For CV test, first fixation of cells with 4% paraformaldehyde for 10 min at
room temperature was done, and then cells were stained with 2% CV solution for 15 min. Finally, cells
were washed with tap water, air-dried, and the dye was dissolved in 33% acetic acid. The absorbance
was measured with an automated microplate reader at 540 nm with a reference wavelength of 670 nm.
The IC50 values were calculated using four-parameter logistic function and presented as mean from
three independent experiments.
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3.6. SRB Assay
SRB assay was performed as reported previously [47]. For SRB assay cells were fixed with 10% of
TCA (trichloroacetic acid) for 2 h at 4 ◦C, washed in distilled water, and stained with 0.4% SRB solution
for 30 min at r.t. Thereafter, cells were washed and dried overnight. The dye was dissolved in 10 mM
TRIS Buffer. The absorbance was measured with an automated microplate reader (Tecan Spectra,
Crailsheim, Germany) at 540 nm with a reference wavelength of 670 nm. The results were expressed
as the percentage of control, nontreated cells. The IC50 values were calculated using four-parameter
logistic function and presented as mean from three independent experiments.
3.7. Annexin V-FITC/PI and Acridin Orange Assays
Cells were cultivated with IC50 doses of experimental drugs for 48 h. Cells were stained with
AnnV-FITC/PI following manufacturer’s instructions. For AO staining, cells were incubated for 15 min
at 37 ◦C in 1 µg/mL of dye solution, washed, and resuspended in PBS. Cells were analyzed with
Attune flow cytometer (Applied Biosystems, Foster City, CA, USA).
3.8. Caspase 3, 8, and 9 Activation Assay
Activity of caspases 3, 8, and 9 was measured using the caspase substrate cleavage assay. After
exposure to IC50 concentrations of investigated compounds, cells were sampled 2 h, 6 h, and 24 h
for cleavage of caspases following manufacturer’s instructions. A specific substrate of caspases 3,
8, and 9 were used. Extinction of released p-nitroaniline was measured at 405 nm (Tecan Spectra,
Crailsheim, Germany) and activity of caspases 3, 8, and 9 was evaluated by optical density (OD) ratio
of treated/untreated samples [48].
4. Conclusions
In this paper, synthesis and characterization of platinum(II) conjugate with BATRIS is reported.
Prepared complex was obtained in almost quantitative yield. Its structure was confirmed with
HR-ESI-MS and multinuclear NMR spectroscopy. In vitro investigations on seven different tumor cell
lines showed that BATRISPt exhibited lower activity than parental drugs BA, BATRIS, or cisplatin
alone. MRC-5 normal fibroblasts were strongly sensitive to cisplatin, BA, and BATRIS, and displayed
limited selectivity toward distinct malignant phenotype such as B16 and HCT116. However, BATRISPt
is triggering apoptosis in B16 cells with lower impact than BA, BATRIS, or cisplatin. Autophagy was
detected in the B16 cell treated with BATRIS, however with its platinum(II) conjugate this process
was not confirmed. Activation of caspases 8 and 9 was more profound in B16 cells upon treatment
with BATRISPt than BATRIS or cisplatin alone. In summary, obtained data indicated that the idea of
hybrid molecule creation through binding of two strong cytotoxic agents with the aim of amplifying
their efficacy will not obviously result in a desirable outcome. On the contrary, overlapping of the two
cytotoxic mechanisms might lead to their neutralization and further point out caution in therapeutic
protocols based on combined treatments.
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Figure A1. HR-ESI-MS of BATRISPt negative mode: (a) measured; (b) calculated spectra for 
{BATRISPt–[K(18-cr-6)]}− ion. 
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